Clinical trial data from drugmaker Novo Nordisk showed that people using Wegovy had a 20% lower risk of a cardiac event than those who got a placebo. In March, the US Food and Drug Administration approved a change that added cardiovascular benefits to Wegovy’s label, making it the first weight-loss drug to be cleared to reduce the risk of heart attack, stroke or heart-related death in people at higher risk of these conditions.
New research … [has] found that GLP-1 drugs could also serve as primary prevention, significantly reducing risk for people with mild or moderate cardiovascular disease who hadn’t had a cardiac event.
…
They found that GLP-1s reduced the risk of heart attack or stroke by 15% to 20%, in line with findings from the clinical trial – but for a broader population, with benefits that could extend to 44 million additional people.
Share this article
With these results, they also estimate that if everyone in this broader population of potentially eligible patients took GLP-1s, it could result in 34,000 fewer heart attacks and strokes each year.
